StockMarketWire.com - Oncology and rare diseases focused Midatech Pharma said it had commenced a study into a treatment for acromegaly and neuroendocrine tumours.

The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin solution for injection on Saturday.

The remaining 14 subjects would undergo the same procedures later this week to complete the dosing phase of the study.

Following MTD201 dosing, all subjects would enter a 63-day observation and sampling period.

The data would then be analysed, with top line results expected by the end of 2019 or early in 2020.




Story provided by StockMarketWire.com